CDEK
← All drugs Report issue

telaglenastat

Small moleculeexperimental

Clinical trial activity

6 trials · 10 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
4
Phase 3
0
Phase 4
0

Earliest trial started Apr 30, 2020 (NCT04265534)

Timeline

2020s

  1. Jan 1, 2020

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2020

    Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

O=C(Cc1cccc(OC(F)(F)F)c1)Nc1ccc(CCCCc2nnc(NC(=O)Cc3ccccn3)s2)nn1
Mol. weight
571.59 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07223528Phase 1/Phase 2 (Phase 2)Nov 30, 2025University of Pittsburgh
NCT05521997Phase 2Jan 31, 2023Calithera Biosciences, National Cancer Institute (NCI), Washington University in St. Louis
NCT04824937Phase 2Jul 31, 2021Calithera Biosciences, Harvard University, Pfizer, Prostate Cancer Foundation
NCT04607512Phase 1Oct 5, 2020Calithera Biosciences, Celerion
NCT04540965Phase 1Sep 22, 2020Calithera Biosciences, Novotech, Nucleus Network Ltd
NCT04265534Phase 2Apr 30, 2020Calithera Biosciences
Showing 6 of 6 trials
Page 1 / 1

Organizations

Research & Development (10)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Calithera BiosciencesFor profit5322020
CelerionFor profit1012020
Harvard UniversityAcademic/Hospital1112021
National Cancer Institute (NCI)Government1012023
NovotechFor profit1012020
Nucleus Network LtdFor profit1012020
PfizerFor profit1012021
Prostate Cancer FoundationAcademic/Hospital1012021
University of PittsburghAcademic/Hospital1112025
Washington University in St. LouisAcademic/Hospital1112023
10 organizations
Page 1 / 1